TOKYO (Reuters) - Japan's Ajinomoto said on Monday it agreed to acquire U.S.-based genetic medicines maker Forge Biologics Holdings for 82.8 billion yen ($546 million).
The transaction is expected to be completed in December 2023 pending regulatory approvals, Ajinomoto said a release.
($1 = 151.7400 yen)
(Reporting by Mariko Katsumura and Rocky Swift in Tokyo; Editing by Tom Hogue)